

04/08/2024

Newly Required PDMP Data Information for CMS Annual Drug Utilization Review Survey for Federal Fiscal

Newly Required PDMP Data Information for CMS Annual Drug Utilization Review Survey for Federal Fiscal Year 2024

Background:

The annual CMS Drug Utilization Review (DUR) Survey contains a new, required section of responses related to the Texas Prescription Drug Monitoring Program (PDMP). This year's survey is for data material from Federal Fiscal Year (FFY) 2023 (Oct. 1, 2022, to Sept. 30, 2023).

Key Details:

CMS now requires Medicaid to report data about prescribing providers' use of PDMPs before prescribing controlled substances. Texas Medicaid obtains this information from the Texas State Board of Pharmacy but does not have access to the PDMP data. A voluntary provider survey created by HHSC will assist HHSC in gathering the required data needed to report on Texas's PDMP usage and meet federal reporting requirements for the following DUR Survey question:

1. The percentage of covered providers (as determined pursuant to a process established by the State) who checked the prescription drug history of a covered individual through a PDMP before prescribing a controlled substance to such an individual.

i. How this information was obtained (through provider survey, provider attestation, PDMP vendor report, raw PDMP data using the median, or another method).

Action:

HHSC will disseminate the survey across multiple platforms and will collect and analyze the responses. HHSC will share a singular answer for all MCOs to use as their response to this question. To maximize provider participation in this survey, HHSC requests MCOs to assist in distributing the survey link as soon as possible to their Medicaid providers. Provider participation in the survey is requested **by April 30, 2024**.

Link to survey: [CMS DUR Annual Survey–Provider PDMP Survey](#)

For the additional PDMP-required questions related to average daily morphine milligram equivalents (MME), HHSC will provide follow-up information for the MCOs to use, which will outline the logic and methodology used to calculate responses for each question. MCOs should follow this process and logic for the MME-related calculations to ensure consistent and comprehensive data collection.

Additional Information:

Instructions for the CMS Annual Drug Utilization Review Survey for FFY 2024 are forthcoming.

Resources:

SUPPORT Act Section 5042 Reporting Tip Sheet_Nov2023 (Attached)

Contact:

vdp-formulary@hhsc.state.tx.us

Attachment:

SUPPORT Act Section 5042 Reporting Tip Sheet_Nov2023.pdf

Type: Informational

To: STAR; STAR+PLUS; STARHEALTH; STAR_KIDS

From: VDP